IBDEI0FB ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,7403,0)
 ;;=V11.3^^55^580^25
 ;;^UTILITY(U,$J,358.3,7403,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7403,1,4,0)
 ;;=4^V11.3
 ;;^UTILITY(U,$J,358.3,7403,1,5,0)
 ;;=5^Hx of Alcoholism
 ;;^UTILITY(U,$J,358.3,7403,2)
 ;;=^295252
 ;;^UTILITY(U,$J,358.3,7404,0)
 ;;=V15.07^^55^580^26
 ;;^UTILITY(U,$J,358.3,7404,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7404,1,4,0)
 ;;=4^V15.07
 ;;^UTILITY(U,$J,358.3,7404,1,5,0)
 ;;=5^Hx of Allergy to Latex
 ;;^UTILITY(U,$J,358.3,7404,2)
 ;;=^322043
 ;;^UTILITY(U,$J,358.3,7405,0)
 ;;=V13.4^^55^580^27
 ;;^UTILITY(U,$J,358.3,7405,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7405,1,4,0)
 ;;=4^V13.4
 ;;^UTILITY(U,$J,358.3,7405,1,5,0)
 ;;=5^Hx of Arthritis
 ;;^UTILITY(U,$J,358.3,7405,2)
 ;;=^295267
 ;;^UTILITY(U,$J,358.3,7406,0)
 ;;=V12.72^^55^580^31
 ;;^UTILITY(U,$J,358.3,7406,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7406,1,4,0)
 ;;=4^V12.72
 ;;^UTILITY(U,$J,358.3,7406,1,5,0)
 ;;=5^Hx of Colon Polyps
 ;;^UTILITY(U,$J,358.3,7406,2)
 ;;=^303401
 ;;^UTILITY(U,$J,358.3,7407,0)
 ;;=V12.59^^55^580^30
 ;;^UTILITY(U,$J,358.3,7407,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7407,1,4,0)
 ;;=4^V12.59
 ;;^UTILITY(U,$J,358.3,7407,1,5,0)
 ;;=5^Hx of CHF
 ;;^UTILITY(U,$J,358.3,7407,2)
 ;;=^303399
 ;;^UTILITY(U,$J,358.3,7408,0)
 ;;=V45.81^^55^580^29
 ;;^UTILITY(U,$J,358.3,7408,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7408,1,4,0)
 ;;=4^V45.81
 ;;^UTILITY(U,$J,358.3,7408,1,5,0)
 ;;=5^Hx of CABG
 ;;^UTILITY(U,$J,358.3,7408,2)
 ;;=^97129
 ;;^UTILITY(U,$J,358.3,7409,0)
 ;;=V15.84^^55^580^28
 ;;^UTILITY(U,$J,358.3,7409,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7409,1,4,0)
 ;;=4^V15.84
 ;;^UTILITY(U,$J,358.3,7409,1,5,0)
 ;;=5^Hx of Asbestos Exposure
 ;;^UTILITY(U,$J,358.3,7409,2)
 ;;=^303406
 ;;^UTILITY(U,$J,358.3,7410,0)
 ;;=V15.85^^55^580^47
 ;;^UTILITY(U,$J,358.3,7410,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7410,1,4,0)
 ;;=4^V15.85
 ;;^UTILITY(U,$J,358.3,7410,1,5,0)
 ;;=5^Hx of Potentially Hazardous Body Fluids
 ;;^UTILITY(U,$J,358.3,7410,2)
 ;;=^303407
 ;;^UTILITY(U,$J,358.3,7411,0)
 ;;=V10.72^^55^580^34
 ;;^UTILITY(U,$J,358.3,7411,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7411,1,4,0)
 ;;=4^V10.72
 ;;^UTILITY(U,$J,358.3,7411,1,5,0)
 ;;=5^Hx of Hodgkin's Disease
 ;;^UTILITY(U,$J,358.3,7411,2)
 ;;=^295237
 ;;^UTILITY(U,$J,358.3,7412,0)
 ;;=V15.3^^55^580^35
 ;;^UTILITY(U,$J,358.3,7412,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7412,1,4,0)
 ;;=4^V15.3
 ;;^UTILITY(U,$J,358.3,7412,1,5,0)
 ;;=5^Hx of Irradiation
 ;;^UTILITY(U,$J,358.3,7412,2)
 ;;=^295285
 ;;^UTILITY(U,$J,358.3,7413,0)
 ;;=V10.61^^55^580^37
 ;;^UTILITY(U,$J,358.3,7413,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7413,1,4,0)
 ;;=4^V10.61
 ;;^UTILITY(U,$J,358.3,7413,1,5,0)
 ;;=5^Hx of Lymphoid Leukemia
 ;;^UTILITY(U,$J,358.3,7413,2)
 ;;=Hx of Lymphoid Leukemia^295232
 ;;^UTILITY(U,$J,358.3,7414,0)
 ;;=V12.03^^55^580^39
 ;;^UTILITY(U,$J,358.3,7414,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7414,1,4,0)
 ;;=4^V12.03
 ;;^UTILITY(U,$J,358.3,7414,1,5,0)
 ;;=5^Hx of Malaria
 ;;^UTILITY(U,$J,358.3,7414,2)
 ;;=Hx of Malaria^303395
 ;;^UTILITY(U,$J,358.3,7415,0)
 ;;=V10.82^^55^580^40
 ;;^UTILITY(U,$J,358.3,7415,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7415,1,4,0)
 ;;=4^V10.82
 ;;^UTILITY(U,$J,358.3,7415,1,5,0)
 ;;=5^Hx of Malignant Melanoma
 ;;^UTILITY(U,$J,358.3,7415,2)
 ;;=Hx of Malignant Melanoma^295240
 ;;^UTILITY(U,$J,358.3,7416,0)
 ;;=V10.62^^55^580^43
 ;;^UTILITY(U,$J,358.3,7416,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7416,1,4,0)
 ;;=4^V10.62
 ;;^UTILITY(U,$J,358.3,7416,1,5,0)
 ;;=5^Hx of Myeloid Leukemia
